Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modeling the cost-effectiveness and budgetary impact for subpopulations.

M J C Nuijten1, J Kosa, P Engelfriet

  • 1MEDTAP International, Amsterdam, The Netherlands. nuijten@medtap.nl

The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|December 21, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Urinary tract infections: Economical impact of water intake].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2015
Same author

The view of European experts regarding health economics for medical nutrition in disease-related malnutrition.

European journal of clinical nutrition·2015
Same author

Comparing ischaemic stroke in six European countries. The EuroHOPE register study.

European journal of neurology·2014
Same author

Increased water intake as a prevention strategy for recurrent urolithiasis: major impact of compliance on cost-effectiveness.

The Journal of urology·2012
Same author

Workshop Report: concepts and methods in the economics of nutrition--gateways to better economic evaluation of nutrition interventions.

The British journal of nutrition·2012
Same author

Cost-effectiveness model for a specific mixture of prebiotics in The Netherlands.

The European journal of health economics : HEPAC : health economics in prevention and care·2010
Same journal

Coordinating care across hospitals: how integration shapes patient mobility.

The European journal of health economics : HEPAC : health economics in prevention and care·2026
Same journal

A comparative analysis of managed entry agreements in Europe: trends, reporting practices, and financial outcomes.

The European journal of health economics : HEPAC : health economics in prevention and care·2026
Same journal

Comparing universal health coverage models: an analysis of policy transmission efficiency in SAARC and ASEAN countries.

The European journal of health economics : HEPAC : health economics in prevention and care·2026
Same journal

Development and validation of solomon's socioeconomic status index (SESI): a multidimensional household classification tool for South Asia.

The European journal of health economics : HEPAC : health economics in prevention and care·2026
Same journal

Who pays and Who benefits? A distributional health-economic evaluation of strengthening the UK soft drinks industry levy.

The European journal of health economics : HEPAC : health economics in prevention and care·2026
Same journal

Getting fairer over time? Assessing changes in health technology funding processes using the accountability for reasonableness (A4R) framework.

The European journal of health economics : HEPAC : health economics in prevention and care·2026
See all related articles

This study presents modeling techniques to identify optimal patient subpopulations for new drugs, considering cost-effectiveness and budget impact. The findings suggest further restrictions may be beneficial for Parkinson's disease treatments.

Area of Science:

  • Health Economics
  • Pharmacoeconomics
  • Health Policy

Background:

  • Increasing demand for health-economic and budgetary-impact data in European healthcare decision-making.
  • Tendency to restrict new drug prescriptions to specific subpopulations based on economic analyses.

Purpose of the Study:

  • To present modeling techniques for determining optimal subpopulations for new drugs.
  • To consider cost-effectiveness and budgetary impact in subpopulation selection.
  • To apply the methodology to a hypothetical Parkinson's disease drug model.

Main Methods:

  • Incorporating confounding variables into Markov health states.
  • Utilizing health state-specific regression equations for costs and utilities.
  • Developing a hypothetical Markov model for a new Parkinson's disease product.

Related Experiment Videos

Main Results:

  • The analysis suggests that further restriction in drug application within registered indications is possible.
  • Cost-effectiveness and budgetary impact support potential application restrictions.
  • The developed methodology can inform decision-making processes for new drug approvals.

Conclusions:

  • Modeling techniques can optimize subpopulation selection for new drugs based on economic factors.
  • Health-economic and budgetary impact analyses are crucial for informed drug prescription decisions.
  • The study provides a framework for refining drug utilization in Parkinson's disease and potentially other conditions.